Regencell Bioscience Holdings Limited (RGC) is a Healthcare stock trading at $12.26 (as of 2026-06-18), with a market capitalization of $11.82B and a trailing P/E of -33.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company focused on researching, developing, and commercializing TCM treatments for neurocognitive disorders and degeneration. Its focus includes conditions such as attention deficit hyperactivity disorder and autism spectrum disorder.